Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): A phase 2B, open-label, randomised controlled trial

1. Park, K.
2. Tan, E.-H.
3. O'Byrne, K.
4. Zhang, L.
5. Boyer, M.
6. Mok, T.
7. Hirsh, V.
8. Yang, J.C.-H.
9. Lee, K.H.
10. Lu, S.
11. Shi, Y.
12. Kim, S.-W.
13. Laskin, J.
14. Kim, D.-W.
15. Arvis, C.D.
16. Kölbeck, K.
17. Laurie, S.A.
18. Tsai, C.-M.
19. Shahidi, M.
20. Kim, M.
21. Massey, D.
22. Zazulina, V.
23. Paz-Ares, L.